The prognostic value of KRAS mutation in locally advanced rectal cancer

Veli Bakalov; Shaakir Hasan; Stephen Abel; Laila Babar; Hira Shaikh; Moses S. Raj; Gene Grant Finley; Dulabh K. Monga; Alexander V. Kirichenko; Rodney E Wegner

doi:10.1200/JCO.2019.37.15_suppl.e15090

Back

The prognostic value of KRAS mutation in locally advanced rectal cancer

Abstract

Open access

Peer reviewed

The prognostic value of KRAS mutation in locally advanced rectal cancer

Veli Bakalov, Shaakir Hasan, Stephen Abel, Laila Babar, Hira Shaikh, Moses S. Raj, Gene Grant Finley, Dulabh K. Monga, Alexander V. Kirichenko and Rodney E Wegner

Journal of clinical oncology, Vol.37(15_suppl), pp.e15090-e15090

05/20/2019

DOI: 10.1200/JCO.2019.37.15_suppl.e15090

Files and links (1)

url

https://doi.org/10.1200/JCO.2019.37.15_suppl.e15090View

Published (Version of record) Open Access

Abstract

Abstract only e15090 Background: The prognostic value and prognostic value of the KRAS proto-oncogene mutation in colorectal cancer has been debated. Herein, we analyzed the National Cancer Database (NCDB) to assess the role of KRAS mutation as a prognostic marker in patients with locally advanced rectal cancer (LARC). Methods: We identified LARC patients treated with neoadjuvant chemoradiation from 2004-2015 excluding those with stage I/IV disease and unknown KRAS status.Multivariable logistic regression identified variables associated with KRAS positivity. Propensity adjusted univariable and multivariable analyses identified predictors of survival. Results: Of the 784 eligible patients, 506 and 278 were KRAS negative (KRAS-) and KRAS positive (KRAS+). Median survival was 63.6 months and 76.3 months for KRAS+ and KRAS-patients, with propensity adjusted 3 and 5-year survival of (79.9% vs. 83.6%) and (56.7% vs 61.9%) respectively (HR 1.56, p 1.074-2.272). Male sex, no insurance, and KRAS+ disease was associated with poorer survival on unadjusted and propensity adjusted multivariable analyses (Table). Conclusions: Our analysis of KRAS+ LARC suggest that KRAS+ disease is associated with poorer overall survival. Given the inherent limitations of retrospective data, prospective validation is warranted. [Table: see text]

Details

Title: Subtitle: The prognostic value of KRAS mutation in locally advanced rectal cancer
Creators: Veli Bakalov - Allegheny Health Network
Shaakir Hasan - Allegheny Health Network
Stephen Abel - Allegheny Health Network
Laila Babar - Allegheny Health Network
Hira Shaikh - University of Cincinnati
Moses S. Raj - Allegheny Health Network
Gene Grant Finley - Allegheny Health Network
Dulabh K. Monga - Allegheny Health Network
Alexander V. Kirichenko - Allegheny Health Network
Rodney E Wegner - Allegheny Health Network
Resource Type: Abstract
Publication Details: Journal of clinical oncology, Vol.37(15_suppl), pp.e15090-e15090
DOI: 10.1200/JCO.2019.37.15_suppl.e15090
ISSN: 0732-183X
eISSN: 1527-7755
Publisher: AMER SOC CLINICAL ONCOLOGY
Language: English
Date published: 05/20/2019
Academic Unit: Internal Medicine
Record Identifier: 9984696768602771

Metrics

4 Record Views